 
 
Official Title:  Fenfluramine in CKDL5 Deficiency Disorder (CDD)   
NCT Number : [STUDY_ID_REMOVED]  
Study Number:  18-01530  
Document Type:   Study Protocol and Statistical Analysis Plan  
Date of the 
Document:  • January 25, 2021  
 
 
  Page i 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017   
  
FENFLURMAINE IN CKDL5 DEFICIENCY DISORDE R (CDD)  
 
Principal Investigator:  
  
Principal Investigator: Orrin Devinsky, MD 
New York University Comprehensive Epilepsy Center  
223 East 34th Street New York, NY 10016 US 
Phone number: 646- 558-0801  
Email: Orrin.Devinsky@nyumc.org 
 
NYULMC Study Number:  s18-01530  
 
Funding Sponsor:  Zogenix I nternational Limited  
Siena Court, Broadway 
Maidenhead, Berkshire SL6 1NJ, United Kingdom  
IND Number:  143731  
Study Product:  ZX008  
Study Product Provider:  Zogenix  
 
Initial version:  [06 June 2019] 
Version 2.0: [25 June 2019] 
Version 3.0: [24 Oct 2019] 
Version 3.0: [09 Sep 2020] 
Version 4.0: [11 Jan 2021] 
Amended:  [date]  
Amended:  [date]  
Amended:  [date]  
Amended:  [date]  
Amended:  [date]  
  
Study number:  s18-01530   Page ii 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017   
Statement of Compliance  
 
This study will be conducted in accordance with the Code of Federal Regulations on the 
Protection of Human Subjects (45 CFR Part 46), 21 CFR Parts 50, 56, 312, and 812 as applicable, any other applicable US government research regulations, and institutional research policies and procedures. The International Conference on Harmonisation (“ICH”) Guideline for Good Clinical Practice (“GCP”) (sometimes referred to as “ICH -GCP” or “E6”) wil l be applied 
only to the extent that it is compatible with FDA and DHHS regulations. The Principal Investigator will assure that no deviation from, or changes to the protocol will take place without prior agreement from the sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed Human Subjects Protection Training.   
Study number:  s18-01530   Page iii 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  Table of Contents 
STATEMENT OF COMPLIA NCE  ................................................................................................................ II 
LIST OF ABBREVIATION S ........................................................................................................................ VI 
PROTOCOL SUMMARY  ............................................................................................................................. 1 
1. KEY ROLES  ......................................................................................................................................... 4 
2. INTRODUCTION, BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ................... 4 
2.1B ACKGROUND INFORMATION AND RELEVANT LITERATURE : NAME AND DESCRIPTION OF THE 
INVESTIGATIONAL AGENT  ............................................................................................................................. 4 
2.1.1  Preclinical Data  ........................................................................................................................ 4 
2.1.2  Clinical Data in Epilepsy  ............................................................................................................ 5 
2.1.3  Dose Rationale (if applicable)  ..................................................................................................... 6 
2.2 RATIONALE  .................................................................................................................................... 6 
2.3 POTENTIAL RISKS & BENEFITS  ........................................................................................................ 6 
2.3.1  Side effects  ................................................................................................................................ 6 
2.3.2  Echocardiogram findings  ............................................................................................................ 7 
3. OBJECTIVES AND PURPO SE ............................................................................................................ 8 
3.1 PRIMARY OBJECTIVE  ...................................................................................................................... 8 
3.2 SECONDARY OBJECTIVES  ............................................................................................................... 8 
4. STUDY DESIGN AND END POINTS  .................................................................................................... 9 
4.1 DESCRIPTION OF STUDY DESIGN  .................................................................................................... 9 
4.2 STUDY ENDPOINTS ......................................................................................................................... 9 
4.2.1  Primary Study Endpoints  ............................................................................................................ 9 
4.2.2  Secondary Study Endpoints  ......................................................................................................... 9 
4.2.3 Safety Endpoints  ............................................................................................................................. 9 
5. STUDY ENROLLMENT AND WITHDRAWAL  .................................................................................. 9 
5.1 INCLUSION CRITERIA  ...................................................................................................................... 9 
5.2 EXCLUSION CRITERIA  ................................................................................................................... 10 
5.3 STRATEGIES FOR RECRUITMENT AND RETENTION  .......................................................................... 11 
5.4 DURATION OF STUDY PARTICIPATION  ............................................................................................ 12 
5.5 TOTAL NUMBER OF PARTICIPANTS AND SITES ................................................................................ 12 
5.6 PARTICIPANT WITHDRAWAL OR TERMINATION  ................................................................................ 12 
5.6.1  Reasons for Withdrawal or Termination..................................................................................... 12 
5.6.2  Handling of Participant Withdrawals or Termination ................................................................. 13 
5.7 PREMATURE TERMINATION OR SUSPENSION OF STUDY  .................................................................. 13 
6 STUDY AGENT  .................................................................................................................................. 14 
6.1 STUDY AGENT DESCRIPTION  ........................................................................................................ 14 
6.1.1  Acquisition  .............................................................................................................................. 14 
6.1.2  Formulation, Appearance, Packaging, and Labeling  ................................................................... 14 
6.1.3  Product Storage and Stability .................................................................................................... 14 
6.1.4  Dosing and Administration ....................................................................................................... 15 
6.1.5  Route of Administration  ............................................................................................................ 15 
6.1.6  Starting Dose and Dose Escalation Schedule  .............................................................................. 15 
6.1.7  Taper Period ........................................................................................................................... 15 
6.1.8  Dose Adjustments/Modifications/Delays  .................................................................................... 15 
6.1.9  Duration of Therapy  ................................................................................................................. 16 
6.1.10  Tracking of Dose ...................................................................................................................... 16 
7 STUDY PROCEDURES AND SCHEDULE  ........................................................................................ 16 
7.1 STUDY SPECIFIC PROCEDURES  .................................................................................................... 16 
Study number:  s18-01530   Page iv 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  7.2 CLINICAL LABORATORY EVALUATIONS  ........................................................................................... 16 
7.3 PROCEDURES  .............................................................................................................................. 17 
7.4 QUESTIONNAIRES  ......................................................................................................................... 17 
7.5 STUDY SCHEDULE  ........................................................................................................................ 18 
7.5.1  Core study  ............................................................................................................................... 18 
7.5.2  Extension  ................................................................................................................................ 22 
7.5.3  End of treatment  ...................................................................................................................... 22 
7.5.4  Unscheduled Visit  .................................................................................................................... 23 
7.6 CONCOMITANT MEDICATIONS  ....................................................................................................... 23 
7.7 PROHIBITED MEDICATIONS , TREATMENTS , AND PROCEDURES  ........................................................ 23 
7.8 PARTICIPANT ACCESS TO STUDY AGENT A T STUDY CLOSURE  ........................................................ 23 
8 ASSESSMENT OF SAFETY  ............................................................................................................... 23 
8.1 SPECIFICATION OF SAFETY PARAMETERS  ...................................................................................... 23 
8.1.1  Definition of Adverse Events (AE)  ............................................................................................. 24 
8.1.2  Definition of Serious Adverse Events (SAE)  ................................................................................ 24 
8.1.3  Definition of Unanticipated Problems (UP)  ................................................................................ 24 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  ....................................................................................... 25 
8.2.1  Severity of Event  ...................................................................................................................... 25 
8.2.2  Relationship to Study Agent  ...................................................................................................... 25 
8.2.3  Expectedness  ........................................................................................................................... 26 
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP .................................... 26 
8.4 REPORTING PROCEDURES – NOTIFYING THE IRB .......................................................................... 27 
8.4.1  Adverse Event Reporting and Serious Adverse Event Reporting  ................................................... 28 
8.4.2  Unanticipated Problem Reporting ............................................................................................. 28 
8.4.3  Reporting of Pregnancy  ............................................................................................................ 28 
8.5 REPORTING PROCEDURES – NOTIFYING THE STUDY SPONSOR  ...................................................... 29 
8.6 REPORTING PROCEDURES – NOTIFYING THE FDA ......................................................................... 29 
8.7 STUDY HALTING RULES ................................................................................................................ 30 
8.8 SAFETY OVERSIGHT  ..................................................................................................................... 30 
9 STATISTICAL CONSIDER ATIONS  ................................................................................................. 30 
9.1 STATISTICAL AND ANALYTICAL PLANS (SAP)  ................................................................................. 30 
9.2 SAMPLE SIZE ............................................................................................................................... 30 
10 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  .................................. 31 
11 ETHICS/PROTECTION OF  HUMAN SUBJECTS ............................................................................. 31 
11.1 ETHICAL STANDARD  ..................................................................................................................... 31 
11.2 INSTITUTIONAL REVIEW BOARD  ..................................................................................................... 31 
11.3 INFORMED CONSENT PROCESS  .................................................................................................... 32 
11.3.1  Consent/Assent and Other Informational Documents Provided to Participants  .............................. 32 
11.3.2  Consent Procedures and Documentation  .................................................................................... 32 
11.4 PARTICIPANT AND DATA CONFIDENTIALITY  .................................................................................... 33 
12 DATA HANDLING AND RECORD KEEPING  .................................................................................. 33 
12.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  .............................................................. 33 
12.2 STUDY RECORDS RETENTION  ....................................................................................................... 34 
12.3 PROTOCOL DEVIATIONS  ............................................................................................................... 34 
13 STUDY FINANCES  ............................................................................................................................ 34 
13.1 FUNDING SOURCE  ........................................................................................................................ 34 
13.2 COSTS TO THE PARTICIPANT  ......................................................................................................... 34 
14 CONFLICT OF INTEREST  POLICY  ................................................................................................ 35 
15  REFERENCES  ....................................................................................................................................... 35 
16. APPENDIX  ............................................................................................................................................ 36 
Study number:  s18-01530   Page v 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017   
          
  
Study number:  s18-01530   Page vi 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017   
List of Abbreviations  
 
 
AE Adverse Event/Adverse Experience  
CFR  Code of Federal Regulations  
CRF  Case Report Form  
CSOC  Clinical Study Oversight Committee  
DCC  Data Coordinating Center  
DHHS  Department of Health and Human Services  
DSMB  Data and Safety Monitoring Board  
FFR Federal Financial Report  
FWA  Federalwide Assurance  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
MOP  Manual of Procedures  
N Number (typically refers to participants)  
NIH National Institutes of Health  
OHRP  Office for Human Research Protections  
OHSR  Office of Human Subjects Research  
PI Principal Investigator  
QA Quality Assurance  
QC Quality Control  
SAE  Serious Adverse Event/Serious Adverse Experience  
SOP Standard Operating Procedure  
US United States  
Study number:   Page 1 
Version: 09 Sep 2020  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor  
Interventional Template Version: 05 JAN 2017  
 Protocol Summary  
Title  Fenfluramine in CKDL5 Deficiency Disorder (CDD)  
Brief Summary  We will enroll 10 patients, ages 2 -35 years old, with a confirmed 
genetic/clinical diagnosis of CDKL5 Deficiency Disorder (CDD) in an open 
label trial of fenfluramine for seizure control.   
 
Protocol – patients will be titrated over 14 days to a dose of ZX008 0.8 
mg/kg/day (maximum dose 30 mg /d) 
Phase  NA 
Objectives  Decrease in seizure frequency and change in impression and quality of life  
Methodology  Open label  
Endpoint Primary outcome:  
Median monthly convulsive seizure frequency  
 Secondary outcomes:  
1. Caregiver/Investigator Global Impression of Change (C/IGIC). The 
parent/caregiver and investigator rated change on a 7- point scale: 1 -very 
much improved; 2 -much improved; 3 -minimally improved; 4 -no change; 
5-minimally worse; 6 -much worse; and 7- very much worse  
2. Quality of Life in Childh ood Epilepsy Scale (13) .  A low -burden 
parent/caregiver completed assessment that looks at how epilepsy affects day-to-day functioning of their child in various life areas, including 
physical activities, well-being, cognition, social activities, behavior and 
general health. 
3. Pediatric Quality Of Life Inventory (PEDS -QL). A parent/caregiver 
completed assessment that looks at how epilepsy affects day- to-day 
functioning of their child in various life areas, including physical activities, well -being, cognition, social activities, beha vior and general 
health during a specific time frame  
Study Duration 14 weeks with extension available  
Duration of IP 
administration  14  weeks with extension available  
Population confirmed genetic/clinical diagnosis of CDKL5 Deficiency Disorder (CDD)  
Study Sites  1: NYU Comprehensive Epilepsy Center.  
Number of participants  10 patient s: 7: ages 2-18 years old  
                    Max of 3: ages 18-35 years old  
Description of Study Agent  Liquid 
Key Procedures Blood draws, questionnaires, Doppler echocardiogram, electrocardiogram 
 
 
Study number:  s18-01530   Page 2 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  Protocol Activity:  
Week ( ±7 days)  Baseline  
Week 0  
 Safety 
call   Week 2 Week 6 Safety call   Week 10  Safety 
call   Week 14  Post 
Taper 
Follow 
up  
Visit  
1 Safety 
call   
2 3 Safety call   
4 Safety 
call  5/End of 
study/ End of 
treatment/ 
Withdrawal 
visit  
Informed consent/assent  X         
Inclusion/exclusion 
criteria  X X X X X X X X  
Medical history  X X X X X X X X X 
Demographics  X  
Physical  and 
neurological exam and 
Vital signs  X  
X X  
X  X  
Adverse events  X X X X X X X X X 
EKG  X   X    X  
Echo  X   X    X  
C/IGIC X  X X  X  X  
QOLCE  X  X X  X  X  
PEDS -QOL  X  X X  X  X  
Hematology & 
Chemistry 
(draw/handling) (CBC, CMP, LFTs, BUN, Creatinine
), Coagulation 
 X  
X X  
X  X  
HCG (urine and serum)  X  X X  X  X  
THC  (urine and serum)  X  X X  X  X  
Urinalysis  X  X X  X  X  
AED levels /Clobazam  X   X  X  X  
Study diary provided  X  X X  X  X  
Study diary collected    X X  X  X  
Study drug dispense d X  X X  X  X*  
Study Drug 
administration  X  
   
    
Study drug compliance 
dosing schedule and 
return dosing schedule  X X X X X X X X X 
Concomitant/other 
medications/supplements  X X X X X X X X X 
Study number:  s18-01530   Page 3 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017   
*If subject continues to extension visit  
 
  Extension  
Protocol 
Activity: 
Week ( ±7 
days)  Exten
sion 
Visit  
 Safety call  Extension 
Visit  
 Safety call  Extension Visit  
 Safety call  End of 
Treatment/
Withdrawal  Post Taper Follow 
up  
Inclusion/excl
usion criteria  X X X X X X X  
Medical 
history  X X X X X X X X 
Physical and 
neurological 
exam and 
Vital signs  X  X  X  X  
Adverse 
events  X X X X X X X X 
EKG  X  X  X  X  
Echo  X  X  X  X  
C/IGIC X  X  X  X  
QOLCE  X  X  X  X  
PEDS -QOL  X  X  X  X  
Hematology 
& Chemistry (draw/handling) (CBC, CMP, LFTs, BUN, Creatinine),  
Coagulation  X  X  X  X  
HCG (urine 
and serum)  X  X  X  X  
THC (urine 
and serum)  X  X  X  X  
Urinalysis  X  X  X  X  
AED levels 
/Clobazam  X  X  X  X  
Study diary 
provided  X  X  X  X  
Study diary 
collected  X  X  X  X  
Study 
dispensed  X  X  X  X  
Study drug 
compliance dosing schedule  and 
return dosing 
schedule  X X X X X X X X 
Concomitant/
other medications/s
upplements  X X X X X X X X 
Study number:  s18-01530   Page 4 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  1. Key Roles 
Principal Investigator: Orrin Devinsky, MD 
New York University Comprehensive Epilepsy Center 223 East 34th Street  
New York, NY 10016 US Phone number: 646-558-0801 Email: Orrin.Devinsky@nyumc.org 
2. Introduction, Background Information and Scientific Rationale  
 
2.1Background Information and Relevant Literature: Name and Description of the Investigational Agent  
Fenfluramine is an amphetamine analogue that was synthesized many years ago. It was 
approved in a large number of countries and widely prescribed as an appetite suppressant for the treatment of adult obesity. Brand names for fenfluramine formulations included Ponderax and Pondimin. Fenfluramine was also used extensively in an off- label combination with phentermine 
(“Fen -Phen”) to treat adult obesity. Fenfluramine is a racemic compound and the single 
enantiomer D -fenfluramine (dexfenfluramine) was also approved and marketed for the treatment 
of obesity as Adifax, Redux, and others. 
Fenfluramine was introduced in the USA in 1973. Products containing fenfluramine and 
D-fenfluramine were withdrawn from all markets between 1997 and 2000 after reports of heart 
valve disease and pulmonary hypertension (Connolly 1997; CDC 1997; Wong 1998). While the  
risk/benefit relationship for fenfluramine was considered unfavorable to treat obesity in adults, establishing seizure control in Dravet syndrome, Lennox-Gastaut syndrome (LGS) or other refractory catastrophic childhood epilepsies might lead to a more acceptable risk/benefit profile for fenfluramine.  The high rate of mortality and severe intellectual and quality of life impairments in severe childhood epilepsies
1, 2 makes any effective drug or therapy a potentially 
life-saving option. 
As a result of the earlier extensive use of fenfluramine in adult obesity , there is a large 
body of information in the public domain concerning its pharmacology, toxicology and use in the treatment of obesity.  These data are summarized in the ZX008 Investigator Brochure (2017).
4 
There is also a large body of information concerning its clinical safety profile.  
2.1.1 Preclinical Data  
The pharmacokinetics of fenfluramine, norfenfluramine and their respective isomers have 
been  studied in mice, rats, dogs and humans. Fenfluramine and norfenfluramine were more 
slowly  eliminated in humans than in other species. In vitro metabolism studies have shown 
considerable species differences in the metabolism of fenfluramine, with no single species having a profile similar to humans. No human- specific metabolites were detected and both rat 
and dog showed good coverage of the human fenfluramine metabolites. In humans, fenfluramine is metabolized  primarily to norfen fluramine. Fenfluramine is partially metabolized by CYP1A2, 
CYP2B6, and CYP2D6, with additional metabolism by CYP2C9, CYP2C19, and CYP3A4. Norfenfluramine  does not appear to be strong substrate of any CYP450 enzyme, but is 
metabolized by CYP1A2, CYP2B6, CYP2C19, and CYP2D6 in vitro. There is also some contribution of renal clearance to the elimination of dexfenfluramine (8% -16%) and 
nordexfenflurmaine (7%-8%) from the body. Because fenfluramine and its active metabolite 
Study number:  s18-01530   Page 5 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  norfenfluramine have multiple pathw ays of  elimination, interference with a single pathway is 
unlikely to cause a significant change in  fenfluramine’s clearance though the probability of an 
interaction increases if multiple elimination mechanisms are affected simultaneously.  
While in vitro s tudies showed that both fenfluramine and norfenfluramine cause weak 
inhibition of CYP2D6 and fenfluramine causes weak induction of CYP3A4 and CYP2B6, 
further analysis  based on the FDA’s mechanistic static model shows that fenfluramine and its 
major metabolite  norfenfluramine are unlikely to alter the pharmacokinetics of substrates of 
CYP450 enzymes in the range of ZX008 doses that will be administered in this study. A 10-week GLP juvenile toxicology and toxicokinetic study in rats, which included fenflurami ne 
doses of 3.5, 9 and 20 mg/kg/day by oral gavage for 10 weeks (Days 7 to 76 pp). The data from the juvenile toxicology studies suggest that the effects of fenfluramine in juvenile animals (CNS -
related clinical signs, effects on body weight and food consumption, and neurobehavioral deficits) are similar to effects previously reported in neonatal and adult rats ( Morford, 2002; 
Williams, 2002). There was no evidence of CNS histopathology; importantly, there were also no histopathologic findings in aortic or mitral cardiac valves, and no adverse effects on any other tissues at necropsy.  
The lowest -observed- adverse- effect level  (LOAEL) of 3.5 mg/kg/day is a human 
equivalent dose (HED) of 0.833 mg/kg/day when converted on the basis of body surface in mg/m2, based on a reference body weight for a 20-kg child. No new target organs were identified in juvenile animals, and there were no permanent effects on sexual maturation or reproductive function when juvenile animals were administered fenfluramine from the neonat al 
period through adulthood.
4 
2.1.2 Clinical Data in Epilepsy  
There have been several published reports of fenfluramine’s successful treatment of 
refractory childhood epilepsy in the 1980s.(Aicardi and Gaustaut, 1985; Aicardi et al., 1988). In 1996, a Belgian group reported on the use of fenfluramine in 11 children (ages 18 months to 15.5 years old) with refractory or self-induced epilepsy (Boel and Casaer, 1996). Patients were treated with fenfluramine at 0.5 – 1 mg/kg/day for 3 to 8.5 years (average duration 5 years 7 months). Seven children (64%) became seizure- free and the remaining 4 patients experienced ≥75% 
reduction in seizure frequency. 
In 2002, Casaer and Boel published an update of their fenfluramine study. The study 
population was expanded to 22 patients with intractable or self -induced seizures, including the 
previous 11 patients (Casaer and Boel, 2002). The duration of treatment was 1 to 12 years.  Among the 22 patients treated, 6 (27%) became seizure-free, 10 (45%) had a 90% reduction in seizure freq uency and 6 (27%) were non-responders. Fenfluramine was effective in multiple 
seizures types in Dravet syndrome (DS), a drug resistant pediatric epileptic encephalopathy syndrome (Ceulemans et al., 2012; Schoonjans 2015 et al,; Ceulemans et al,, 2016). 
4 
Zogenix is currently evaluating ZX008 in DS in three Phase 3 double-blind, randomized, 
placebo -controlled studies (clinicaltrials.gov identifiers: [STUDY_ID_REMOVED], [STUDY_ID_REMOVED], and 
[STUDY_ID_REMOVED]).  Currently, a cohort of refractory Lennox-Gastaut syndrome (LGS) patients in Belgium are being treated in a Phase 2 open -label, pilot, dose-finding trial of fenfluramine as an 
add-on therapy to conventional therapy (Study S58545; clinicaltrials.gov identifier: 
[STUDY_ID_REMOVED]). Subjects aged 3 to 18 years, fulfilling the diagnostic criteria for LGS as described by the International League Against Epilepsy (ILAE) in 1989, who have failed at least two AEDs (including vagal nerve stimulation (VNS), and have had at least 4 documented convulsi ve seizures (generalized tonic-clonic, tonic, atonic, and focal seizures with a motor 
Study number:  s18-01530   Page 6 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  component and on at least 2 AEDs at stable doses in the prior 4 weeks are eligible for this study 
(Lagae et al., 2016).  A similar study has been initiated in the United States.4 
For the Belgium LGS study, subjects establish baseline convulsive seizure frequency 
over 4 weeks and are then treated with fenfluramine at a starting dose of 0.2 mg/kg/day. In non-responders (<50% convulsive seizure frequency decrease), the dose is up titrated every 4 weeks from 0.2 mg/kg/day to 0.4 mg/kg/day, and up to a maximum dose of 0.8 mg/kg/day for up to 20 weeks if the patient remains a non -responder per protocol definition.
4 
Interim results are available on the anticonvulsant effects of adjunctive treatment with 
ZX008 in the first 13 patients with LGS from Study S58545 (9 males, 4 female).  Fenfluramine treatment was started at a mean age of 11.4 years (range 3 to 17 years), administered at a maximum of 0.8 mg/kg/day and added to each patient’s current AED regimen. Prior to enrolling in the trial,  all patients  had failed  on at  least  3 other  AEDs. By November 2016, 8 patients had 
completed  all 20 weeks of the treatment period, 4 patients withdrew before study end, and  1 
patient remained  on treatment,  having completed  16 weeks o f treatment.  Of the  4 patients who 
withdrew before  study end, 1 withdrew due to  worsening of seizures following elective surgery,  
and 3 withdrew due to  adverse events  (2 decreased  alertness,  1 insomnia). Seven of the 13 
patients (54%) achieved at least a 50% reduction in the number of convulsive seizures during the study at doses of 0.2mg/kg (3 patients), 0.4mg/kg (3 patients) and 0.6mg/kg (1 patient). Despite not attempting to dose to maximal efficacy a dose response appears to be emerging with a 2 -fold 
increase in the number of responders at the 0.4 mg/kg/day vs. 0.2 mg/kg/day dose. The most common treatment emergent adverse events to date include decreased appetite in 3 patients, decreased alertness/fatigue in 3 patients, and insomnia in 2 patients. ZX00 8 has been well 
tolerated in this small, open -label study, and no patients have exhibited any clinical signs of 
cardiovascular or cardiopulmonary adverse events as of the November 2016 data cut. 
(ZX008 IB 2017).
4 
2.1.3 Dose Rationale  
Based on clinical data to d ate. Patient will be dosed up to 0.8 mg/kg/d or 30 mg/d 
maximum. It will be twice daily dosing. Fenfluramine was administered to over 500 children with neurobehavioral conditions, including autism and ADHD with good safety and tolerability, at doses in the range of 0.65 to 3.6 mg/kg/day (most common dose of 1.5 mg/kg/day) for up to 12 months.
4 
2.2 Rationale 
The lack of consistent efficacy and individual tolerability and safety concerns with 
current treatments available have resulted in the continued significant unmet need for a new treatment with a novel mechanism of action for children and adults with CDD. 
2.3 Potential Risks & Benefits  
Fenfluramine is effective in multiple seizures types in Dravet syndrome (DS), another 
very drug resistant pediatric epileptic encephalopathy syndrome.  In a recent Phase III study of 119 DS patients, the median reduction of convulsive seizures was 64% greater than placebo
3 in 
the group that received 0.8 mg/kg/day and 34% for the group that received 0.2 mg/kg/day of fenfluramine.  
2.3.1 Side effects 
The most common AEs observed in children and young adults the ongoing studies of 
Study number:  s18-01530   Page 7 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  ZX008 include decreased appetite, pyrexia, diarrhea, lethargy, and somnolence.  However, there 
is limited data in the pediatric population, largely based on the B elgium and the more recent 
Phase 3 trial cited above.4 
2.3.2 Echocardiogram findings  
Findings from echocardiograms will be discussed between the investigator, local cardiologist and 
parent/caregiver/legal or authorized representative to determine risk versus benefit of the study to 
the subject.  
ECHOs will be done at NYU. If caregivers/patients are not able to travel to NYU 
facility, doppler echocardiography can be done at a local facility.  Readings will be sent back 
to site  for evaluation.  Findings related to pulmonary hypertension or valvulopathy on any of 
the four valves (aortic, mitral, pulmonary, tricuspid) will be reported to the investigator with grades of normal, trace, mild, moderate or severe. If the ECHO result has progressed in severity since the last reading, then new oversight measures will be enacted as described below in Levels 1-3. Table 12 describes the severity of ECHO findings with the level of increasing oversight if the subject is to remain in the study.  
 
Table 1: Clinical Measures Enacted Upon Increasing Severity of ECHO Findings  
 
 
Severity  Valve  
Aortic  Mitral  Pulmonary  Tricuspid  
Normal  Level 1  Level 1  Level 1  Level 1  
Trace  Level 2  Level 2  Level 1  Level 1  
Mild  Level 2  Level 2  Level 1  Level 1  
Moderate  Level 3  Level 3  Level 3  Level 3  
Severe  Level 3  Level 3  Level 3  Level 3  
 
Level 1: Continue per protocol  
Level 2:  
1. If there is a desire to continue study medication:  
a. The investigator will evaluate the efficacy to date based on study diaries 
and consult with the parent/guardian, and determine whether study 
treatment was associated with significant, meaningful benefit in number, severity and/or duration of seizures and/or on the impact on 
daily  functioning. 
b. The investigator will consider whether the subject has had reasonable trials 
(dose and duration) of other available anticonvulsants (e.g. valproic acid, 
clobazam, or topiramate), alone or in combination, and not maintained the level of seizure control achieved with study medication.  
2. If the investigator feels consideration of continue d treatment is warranted 
considering benefit and potential risk, and the parent/guardian feels strongly that the child be maintained on the study medication when understanding the risks, the parent/guardian must sign a new consent which describes the additional risk and the child should provide assent if appropriate. 
a. If both of these conditions are not met, the subject is discontinued 
from  treatment.  
Study number:  s18-01530   Page 8 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  3. Investigator and Institutional Cardiologist make  a determination of appropriate path, 
including the possible outcomes:  
a. Discontinue study medication  
b. Increase frequency of ECHO and ECG  monitoring 
c. Add additional ECG and/or ECHO measures to be monitored 
d. Reduce the dose of study medication  
Level 3:  
1. The investigator will evaluate efficacy to date based on study diaries and consult 
with the parent/guardian, and determine whether the achieved benefit justifies 
the consideration of continuing study treatment. MIN IMAL efficacy criteria : 
a. Seizures must be more than 75% improved (number of convulsive 
seizures per 28 days) on treatment over baseline, and improvement must be consistent. 
b. The number, type, duration, and distribution of seizures at baseline should be 
of a severity, which justifies the risks of cardiopulmonary complications, considering the subject’s age and overall  health.  
c. Subject has had reasonable trials (dose and duration) of other available anticonvulsants (e.g., valproic acid, clobazam, topiramate), alone or in combination, and not maintained the level of seizure control achieved with study medication.  
2. If the investigator feels consideration of continued treatment is warranted 
considering benefit and potential risks, and the parent/guardian feels strongly that the child be maintained on the study medication when understanding the risks, the parent/guardian must sign a new consent, which describes the additional risks and the child should provide assent if possible. 
a. If both of these conditions are not met, the subject is discontinued 
from  treatment.  
3. Investigator and Institutional Cardiologist make  a determin ation of appropriate path, 
including these possible outcomes: 
a. Discontinue study medication  
b. Increase frequency of ECHO and ECG  monitoring 
c. Add additional ECG and/or ECHO measures to be monitored 
d. Reduce the dose of study medication  
3. Objectives and Purpose  
3.1 Prim ary Objective 
Median reduction in monthly convulsive seizure frequency 
3.2 Secondary Objectives  
o Caregiver/Investigator  Global Impression of Change (C /IGIC).  The parent/caregiver and 
investigator rated change on a 7 -point scale: 1 -very much improved; 2-much improved; 
3-minimally improved; 4 -no change; 5 -minimally worse; 6 -much worse; and 7 -very 
much worse 
o Quality of Life in Childhood Epilepsy Scale .  A low-burden parent/caregiver com pleted 
assessment that looks at how epilepsy affects day -to-day functioning of their child in 
Study number:  s18-01530   Page 9 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  various life areas, including physical activities, well-being, cognition, social activities, 
behavior and general health in comparison to other children their age,  
o PEDS -QL. A parent/caregiver completed assessment that looks at how epilepsy affects 
day-to-day functioning of their child in various life areas, including physical activities, 
well-being, cognition, social activities, behavior and general health during a specific time 
frame.  
4. Study Design and Endpoints  
4.1 Description of Study Design 
The study to be conducted is  an expanded access program for intermediate size 
population use. 
 
4.2  Study Endpoints 
4.2.1 Primary Study Endpoints  
Median reduction in monthly convulsive seizure frequency. For continuation after initial 
study period, patients must have a ≥  40% reduction in convulsive seizure frequency over 
baseline.  
4.2.2 Secondary Study Endpoints  
Evaluate changes from Baseline in cognitive, motor, and behavioral f unction as well as  
QOL following fenfluramine treatment.  
4.2.3 Safety Endpoints  
The safety endpoints the study are: 
• Adverse events  
• Laboratory safety (hematology, chemistry,  coagulation, urinalysis) 
• Vital signs (blood pressure, heart rate, temperature, and respiratory rate)  
• Physical examination  
• Neurological examination  
• Questionnaires to measure changes in cognition of the subject 
• 12-lead ECGs  
• Doppler ECHOs  
• Body weight  
5. Study Enrollment and Withdrawal  
All subjects and/or their parent/legal guardian must sign the appropriate informed consent 
prior to beginning any study-related activities, including Screening procedures. Additionally, an assent form should be signed by subjects age 7 to 17 years old, unless lacking capacity. 
5.1 Inclusion Criteria  
In order to be el igible to participate in this study, an individual must meet all of the  
following criteria : 
1. Confirmed clinical/genetic diagnosis of CDKL5 Deficiency Disorder CDD 
Study number:  s18-01530   Page 10 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017   
2. Ages 2 -35 years old. Subject is male or non-pregnant, non- lactating female.  
Female subjects of childbearing potential must not be pregnant or breast- feeding. Female 
subjects of childbearing potential must have a negative urine pregnancy test. Subjects of childbear ing or child -fathering potential must be willing to use medically acceptable 
forms of birth control, which includes abstinence, while being treated on this study and for 30 days after the last dose of study drug. 
 
 3. Subject has been informed of the nature of the study and informed consent has 
been obtained from the legally responsible parent/guardian.  4. Subject has provided assent in accordance with Investigational Review 
Board/Independent Ethics Commi ttee (IRB/IEC) requirements  
 
 5. Subject’s caregiver is willing and able to be compliant with diary completion, 
visit schedule and study drug accountability.  6. Subjects must be receiving a therapeutically relevant and stable dose of anti -
seizure medications, dietary therapies for epilepsy or vagus nerve stimulation settings for at least 4 weeks prior to screening and are expected to remain stable throughout the i nitial 
14 weeks of the study.  Medication changes are allowed during the extension portion. 
 
 7. ≥4 convulsive seizures (tonic -clonic, tonic, atonic, clonic, focal motor) per 4-
week period; each convulsive seizure must last ≥3 seconds.  
 8. Subject is r eceiving at  least 1 concomitant AED and up to 4 concomitant AEDs, 
inclusive. KD and VNS are permitted but do not count towards the total number of AEDs. Rescue Receiving at least 1 concomitant AED and up to 4 concomitant AEDs, inclusive. Rescue medications for seizures are not counted towards the total number of AEDs.  
 
5.2 Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation 
in this study:  
1. Subject has a known hypersensitivity to fenfluramine or any of the excipients in 
the study medication.  
 2. Subject has current or past history of cardiovascular or cerebrovascular disease, 
myocardial infarction or stroke. 
 
3.  Subject has current or past history of cardiovascular or cerebrovascular disease, 
such as cardiac valvulopathy, myocardial infarction or stroke, or clinically significant structural cardiac abnormality, including but not limited to mitral valve prolapse, atrial or ventricular septal defects, patent ductus arteriosis, and patent foramen ovale 
Study number:  s18-01530   Page 11 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  with reversal of shunt. (note: Patent foramen ovale or a bicuspid valve are is not 
considered exclusionary, but may be associated with the following diseases, which are exclusionary: coarctation of the aorta, Turner syndrome, supravalvular aortic stenosis, subvalvular aortic stenosis, patent ductus arteriosus, Sinus of Valsalva aneurysm, ventricular septal defect, Shone’s complex, ascending aortic aneurysm, Loeys -Dietz syndrome, ACTA2 mutation familial thoracic aortic aneurysm 
syndrome, and MAT2A mutation familial thoracic aortic aneurysm syndrome).  
 
4. Subject has current or recent history of Anorexia Nervosa, bulimia, or depression 
within the prior year that required medical treatment or psychological treatment for a duration greater than 1 month. 
 
5.  Subjects who are currently on formulations of CBD (other than Epidiolex) , 
CBD/THC or any MMJ.  
 
6. Subject who have  positive urine tetrahydrocannabinol (THC) Panel or whole blood 
cannabidiol (CBD) who have not been prescribed Epidiolex. 
 7. Subject has participated in another clinical trial within the past 30 days (calculated 
from that study’s last scheduled visit).
 
 8. Subject is at imminent risk of self -harm or harm to others, in the investigator’s 
opinion, based on clinical interview.     9. Subject has a current or past history of glaucoma.  
 
10.  Subject is receiving concomitant therapy with: centrally -acting anorectic  
agents; monoamine- oxidase inhibitors; any centrally -acting compound with 
clinically appreciable amount of serotonin agonist or antagonist properties, including serotonin reuptake inhibition; atomoxetine, or other centrally-acting noradrenergic agonist; or cyproheptadine. (see appendix 1)  
11. Subject has moderate or severe hepatic impairment. Asymptomatic subjects with 
mild hepatic impairment (elevated liver enzymes <3x upper limited of normal [ULN] and/or elevated bilirubin <2x ULN) may be entered into the study after review and approval by the Medical Monitor in conjunction with the sponsor, in consideration of comorbidities and concomitant medications.  
5.3 Strategies for Recruitment and Retention  
During a routine visit at the NYU Comprehensive Epilepsy Center, subjects who meet 
criteria for the study (or their parents/legal guardians) will be asked if they would like to participate in the study. Note: some subjects may hear of this study fr om other parents with CDD 
or from the International Foundation for CDKL5 Research (https://www.cdkl5.com), which lists studies for patients with CDD.  Such subjects who contact the Principal Investigator or research staff will be screened for their potenti al to participate based on inclusion and exclusion criteria.   
Male and female subjects of any ethnicity between ages of 2  and 35 ( inclusive) will be 
Study number:  s18-01530   Page 12 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  assessed for inclusion , with no more than 3 patients between the ages of 18-35.  
During the routine visit,  the investigator will inform each prospective  
subject/parent/legal guardian of the nature of the study, and explain the potential risks and 
study-related procedures. If the subject/parent/legal guardian agrees, they will be given the informed consent documents to read and sign prior to starting any study procedures. Only the Principal Investigator, sub-investigators, and other research personnel listed on the study will have access to subject information. Once the study subject/parent/legal guardian has signed the informed consent, the investigator will explain the study during the routine visit. If necessary, the investigator will inform the subject and surrogate that a capacity assessment will be performed to determine whether the subject is capable o f providing an informed decision to participate in the 
study. At this time, a capacity assessment will be conducted if the subject does not refuse the assessment. Capacity will be assessed through neurological examinations and neuropsychology reports condu cted by the physician as well as learning and/or development delays that have been 
documented. If there is already documentation of lack of capacity, no assessment will be needed. If it has been determined by the investigator that the subject has capacity,  they will be given the 
assent form to review. The investigator will go over the study as described in the assent form including study visits and procedures. The subject will be allowed time to ask questions. If the subject is comfortable, then they can sign the assent. All documentation will be placed in the study binder and documented in the study visit note. A copy of the informed assent and consent documents will be given to the subject and the subject’s parent/legal guardian. Screening procedures may begin. The Screening Period is 4 weeks, during which study candidates must complete a diary documenting the frequency and duration of seizures.  
Refer to Section 7 for the Schedule of Events and specific requirements for each study 
visit.  
5.4 Duration of Study Participation  
Subject participation will be a total of 14 weeks with extension available.  
5.5 Total Number of Participants and Sites  
Approximately 10 patients with a confirmed genetic/clinical diagnosis of CDKL5 
Deficiency Disorder (CDD) will be recruited fo r the study from the Principal Investigator’s and 
co-investigator’s clinical practice at New York University Comprehensive Epilepsy Center 
(NYUCEC) or from families that contact the Principal Investigator. Male and female subjects of any ethnicity between ages of 2 and 35 ( inclusive) will be assessed for inclusion , with no more 
than 3 patients between the ages of 18-35.  
5.6 Participant Withdrawal or Termination  
5.6.1 Reasons for Withdrawal or Termination  
 A subject may be discontinued from study drug at any time if the subject, subject’s legal  
guardian, or the investigator feels that it is not in the subject’s best interest to continue. The following is a list of possible reasons for study drug discontinuation: 
1. Parental/legal guardian withdrawal of consent.  
2. Subject is not compliant with study procedures.  
Study number:  s18-01530   Page 13 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  3. Protocol violation requiring discontinuation of study drug. 
 
4. Severe adverse events, including significant toxicity such as severe cognitive or  
behavioral toxicity, impaired liver and renal function, or impaired hematopoiesis  
 5. Seizure exacerbation not attributable to other known provocative factors. 
 
6. Interaction with concomitant AED regimen that leads to unacceptable toxicity.  
Medication adjustments will be avoided, if possible, and may require the subject to exit the study, at the discretion of the Investigator. 
 Specific drug -related toxicities will be assessed and managed by the Principal Investigator.  
 
Depending on the nature of the signs (eg, changes in serum chemistries, liver function 
tests) or  symptoms  (eg, rash), the subject will be assessed to determine the severity and 
likelihood of relation to study medication. Based on this assessment, the medication may be discontinued, the dose may be reduced, or the drug may be continued with ongoing assessment. If the study drug is discontinued due to a suspected toxicity, it will only be restarted if there is strong evidence that  the toxicity was likely not related to the study medication (eg, liver tests 
were elevated due to a cytomegalovirus infection).  
If a subject must discontinue study drug, the method for discontinuation from study drug 
will be  determined based on the type of reaction and/or reason for withdrawal. For example, if 
the subject experiences a rapidly progressive rash, it would lead to abrupt cessation of study drug, but if subject experiences excess tiredness, study drug may be tapered off. A discussion of the method of cessation will occur between the subject and/or subject’s parent/legal guardian and the physician.  
5.6.2 Handling of Participant Withdrawals or Termination 
For all subjects who withdraw from the study, there will be 1 final telephone /email 
follow-up 4 weeks after the last dose of study drug (Post taper Follow- up Visit). If the 
subject/parent/legal guardian cannot be contacted after 4 phone calls to subject/parent/legal 
guardian, a certified letter will be sent to the subject/parent/legal guardian.  
 
Refer to Section 7 for the Schedule of Events and specific requirements for each study visit.  
5.7 Premature Termination or Suspension of Study 
This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause. Written notification, documenting the reason for study suspension or termination, will 
be provided by the suspending or terminating party to Princ ipal investigator. If the study is prematurely 
terminated or suspended, the PI will promptly inform the IRB and will provide the reason(s) for the termination or suspension.  
 
Circumstances that may warrant termination or suspension include, but are not lim ited to:  
• Determination of unexpected, significant, or unacceptable risk to participants 
• Demonstration of efficacy that would warrant stopping 
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable 
Study number:  s18-01530   Page 14 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  • Determin ation of futility  
Study may resume once concerns about safety, protocol compliance, data quality is addressed and 
satisfy the sponsor, IRB and/or FDA.  
 
6 Study Agent   
Investigational Medicinal Product – ZX008  
Substance Code  ZX008  
Active Substance (INN)  Fenfluramine Hydrochloride  
Trade Name  Not applicable  
Formulation (including dosage form and strength)  Solution  2.5mg/mL  
Route/Mode of Administration  Oral 
Manufacturer  Andersonbrecon, Inc . on behalf of Zogenix  
International Limited  
6.1 Study Agent Description  
ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered 
to pH 5 and provided in concentrations of 2.5 mg/mL. The excipients selected have been 
approved for use in the formulations of currently marketed drug products and are considered to be safe. The solution formulations will be suitably flavored, and will contain preservatives and a thickening agent. The product is sugar free and is intended to be compatible with a ketogenic diet.  The doses to be studied will be 0.8 mg/kg/day divided into two daily doses, up to a maximum o f 30 mg/day.  
6.1.1 Acquisition  
The investigational medicinal product (IMP) will be supplied to the study site by the 
sponsor or its delegate. 
All IMP will be transported, received, stored, and handled strictly in accordance with the  
container or product label, the instructions supplied to the research site and its designated pharmacy, the site’s standard operating procedures, and applicable regulations. IMP must be stored separately from normal hospita l or practice inventories, in a locked facility with access  
limited to the investigator and authorized personnel. The investigator must ensure that the IMP is dispensed only to subjects enrolled in this study according to this study protocol. 
6.1.2 Formulation, Appearance, Packaging, and Labeling  
ZX008 drug product will be provided in a concentration of 2.5 mg/mL in 1 bottle size 
with nominal fill volume of 120 ml.  The ZX008 product will be packaged and labeled according 
to current International Conference on Harmonization (ICH), Good Manufacturing Practices (GMP), and Good Clinical Practices  (GCP) guidelines, and national legal requirements. 
Dosing directions for the product can be found in the IMP handling instructions for the 
study subjects and for the inves tigator.  
6.1.3 Product Storage and Stability 
Appropriate storage temperature and transportation conditions will be maintained for the 
study drug from the point of manufacture up to delivery of the study drug. Study medication must be stored at 15-25°C (59-77°F) with excursions of 5-30°C (41-86°F) permitted; do not 
Study number:  s18-01530   Page 15 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  refrigerate or freeze.  Storage and handling instructions of the IMP maintained at the subject’s 
home are described in  the subject’s IMP handling instructions. 
All unused IMP will be saved by the site for final disposition according to the sponsor’s 
directive.  
6.1.4 Dosing and Administration  
Study medication will be administered as equal doses BID in the morning and in the 
evening  approximately 12 hours apart. Each dose should be separated by a minimum of 8 hours 
and a maximum of 12 hours. 
6.1.5 Route of Administration  
Medication is given orally.  
6.1.6 Starting Dose and Dose Escalation Schedule  
Patients will be titrated over 14 days to a dose of ZX008 0.8 mg/kg/day (maximum dose 
30 mg/d). 
Titration schedule  
  Day 1 -4 Day 5-8 Day 9 -14 
ZX008 0.2 
mg/kg/day  ZX008 0.4 
mg/kg/day  ZX008 0.8 
mg/kg/day  
 
After completion of the Titration Period, subjects will enter the Maintenance Period and 
continue to receive this dose of ZX008 and be treated for an additional 12 
weeks. Study medication will continue to be administered BID in the morning and in the evening, approximately 12 hours apart. Each dose should be separated by a minimum of 8 hours and a maximum of 12 hours. A missed dose of study medication may be taken later up to 8 hours before the next scheduled dose; otherwise, the missed dose should not be given.  
6.1.7 Taper Period  
Subjects will decrease from 0.8 mg/kg BID to a dose of 0.4 mg/kg BID (maximum 30 
mg/day or). After 4 days at this dose level, subjects will decrease their dose to 0.2 mg/kg/day.  On Study Da y 9, all subjects will stop taking study medication. The taper is expected to take a 
total of 8 days. 
Taper schedule  
 Day 5 -8 after end of 
study/ study 
withdrawal  Day 9 -14 after end of 
study/ study 
withdrawal  
ZX008 0.4 mg/kg/day  ZX008 0.2 mg/kg/day  
 
6.1.8 Dose Adjustments/Modifications/Delays  
A missed dose of study medication may be taken later up to 8 hours 
before the next scheduled dose; otherwise, the missed dose should not be given. 
If the parent/caregiver is unable to administer the full dose due to spillage (eg, dose was 
spilled  during measuring, subject spit dose out during administration), he/she should attempt to 
give the full dose noting the extra amount used to fulfill the dose. If the subject vomits within the first 15  minutes of administration the dose may be re -administered. Care must be taken not to 
overdose. If the amount spilled is not known, the parent/caregiver should not give additional 
Study number:  s18-01530   Page 16 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  medication to  avoid potential overdose. 
6.1.9 Duration of Therapy  
Duration of therapy will be14 weeks with extension available.  
6.1.10  Tracking of Dose  
The study team will assess and track subject compliance with the study drug regimen via 
clinical  evaluations and follow-up email or phone calls.  
7 Study Procedures and Schedule  
7.1 Study Specific Procedures  
-Medical history: Any  medical problems/conditions throughout subject’s body system, 
relevant medical events and/or procedures/surgery  
  -Medication history: complete  medication history of any anti- epileptic medications; 
current history other prescription and over- the-counter medications.  
 -Physical examination: vital signs including temperature, height and weight and organ systems to be assessed  
 -Neurological examina tion: examination of sensory neurons, motor responses and 
reflexes  
 -Biological specimen collection and laboratory evaluations.   -Procedures: Doppler Echocardiography and Electrocardiograms   -Questionnaires and seizure diary  
7.2 Clinical Laboratory Evaluatio ns 
-Hematology:  hemoglobin, hematocrit, white blood cells (WBC) with differential count, 
platelet count.  
 -Coagulation:  Prothrombin time (PT)/International normalized ratio (INR), activated  
partial thromboplastin time (PTT)  
 -Biochemistry:  comprehensive metabolic panel, creatinine, total bilirubin, alanine 
aminotransferase (ALT), aspartate and aminotransferase (AST)
 albumin (ALB), alkaline  
phosphatase (AP), alanine  aminotransferase (ALT; SGPT), aspartate aminotransferase 
(AST; SGOT),  bicarb onate, blood urea nitrogen (BUN), calcium (Ca), carbon dioxide 
(CO2),chloride (Cl), creatinine, creatine kinase, gamma- glutamyl transferase (GGT),  
globulin, glucose, lactate dehydrogenase (LDH), phosphorus, potassium (K), sodium (Na), thyroid function (T3, T4, and thyroid stimulating hormone [TSH]), total bilirubin, direct bilirubin, total cholesterol, total protein, triglycerides, uric acid.  
 
Study number:  s18-01530   Page 17 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  -Urinalysis:  dipstick urinalysis, including protein, hemoglobin and glucose; if dipstick is 
abnormal, complete urinalysis with microscopic evaluation is required. 
 -Urine or serum pregnancy test:  usually to be done within 24 hours prior to study 
intervention and results must be available prior to administration of study product.  - Urine or serum THC test:  usually to be done within 24 hours prior to study 
intervention and results must be available prior to administration of study product.  -Plasma Sample for Concomitant Antiepileptic Drug(s): Plasma samples to ensure that 
concomitant AEDs dosing is within a n acceptable range will be conducted during the study 
as outlined. 
 
Blood work will be about 8.0 – 20.0mL (about 2-4 teaspoons) of blood depending on the amount of concomitant medications .  
 
If caregivers/patients are not able to travel to the NYU facility  due to COVID-19 travel 
restrictions , clinical laboratory evaluations  can be completed  at a local facility . 
7.3 Procedures  
Electrocardiograms:  Twelve-lead ECGs will be conducted during study as outlined 
after the subject has been in the supine position resting for ≥5 minutes. Heart rate, PR 
duration, QRS duration, QT duration, and the investigator’s overall interpretation will be recorded.  
 
Doppler Echocardiography:  Doppler echocardiography will be conducted at the 
hospital facility with experience for the subj ect’s age. If caregivers/patients are not able 
to travel to NYU facility, doppler echocardiography can be done at a local facility. Doppler echocardiography can be done +/- 7 days from study visit. Doppler echocardiography uses ultrasound technology to examine the heart or blood vessels. An ECHO uses high frequency sound waves to create an image of the heart while the use of Doppler technology allows determination of the speed and direction of blood flow by utilizing the Doppler effect. Predetermined standa rd guidelines on the proper evaluation 
of certain measurements, as well as abnormality thresholds, were constructed by the sponsor prior to study initiation. Readings will be sent back to site to determine the appropriate benefit is and any findings consistent with cardiac valvopathy or pulmonary hypertension.   
7.4 Questionnaires  
*Given the profound intellectual disability of this population (ie, adults have intelligence of <age 5), the pediatric versions will be used for both children and adults. *  
-Caregiver Global Impression of Change (CGIC). The parent/caregiver rated change 
on a 7- point scale: 1 -very much improved; 2-much improved; 3- minimally improved; 4 -
no change; 5 -minimally worse; 6 -much worse; and 7 -very much worse 
-Investigator Global Impression of Change (I GIC).  The investigator rated change on a 
Study number:  s18-01530   Page 18 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  7-point scale: 1 -very much improved; 2-much improved; 3- minimally improved; 4 -no 
change; 5 -minimally worse; 6 -much worse; and 7-very much worse 
-Quality of Life in Childhood Epilepsy Scale (13) .  A low- burden parent/caregiver 
completed assessment that looks at how epilepsy affects day -to-day functioning of their 
child in various life areas, including physical activities, well-being, cognition, social 
activities, behavior and general health in comparison to other children their age,  
-Pediatric Quality of Life Inventory (PEDS- QL). A parent/caregiver completed 
assessment that looks at how epilepsy affect s day- to-day functioning of their child in 
various life areas, including physical activities, well-being, cognition, social activities, 
behavior and general health during a specific time frame 
7.5 Study Schedule  
7.5.1 Core study  
7.5.1.1 Baseline  
Visit 1 Baseline (Week 0 ) 
Baseline ( Visit 1) will occur at NYU CEC.  P rocedures will proceed as follows: 
• Obtain written informed consent/assent. 
• Determine if the subject meets the preliminary eligibility criteria:  
o Collect demographic information  
o Collect current and relevant medical  history 
o Identify concomitant medications used  
o Identify and confirm stable use AED medications  
o ≥4 convulsive seizures (tonic -clonic, tonic, atonic, clonic, focal motor) per 4-
week period; each convulsive seizure must last ≥3 seconds.  
If the subject meets the preliminary eligibility criteria, the following assessments will be performed:  
• Vital signs (including systolic and diastolic blood pressure, radial pulse rate, and body temperature): perform in sitting position  
• Physical and neurological examination inc luding Height and weight 
• EKG and echocardiogram  
• Complete the following assessments: 
o Caregiver  and Investigator  Global Impression of Change  
o QOLCE  
o PEDS -QOL  
• Blood draw for clinical laboratory evaluations: 
o Complete blood count (CBC), comprehensive metabolic panel (CMP) Serum/Urine human chorionic gonadotropin (HCG), as applicable (sample taken only for female subjects of childbearing potential), and antiepileptic medication levels  
Study number:  s18-01530   Page 19 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  • Urinalysis  
• Urine or serum THC  
• Record any AEs occurring since signing the ICF and any that occur during this visit 
• Instruct subject or subject’s caregiver to keep a seizure diary for the next 2 weeks, including 
the following information: 
o Seizure type and duration  
o Use of rescue medications  
• Dispense study drug and review administration instructions  and titration schedule 
• First dose given in office 
• Instruct subject to return in 2 weeks for Visit 2 
Safety call telephone  
The safety call will occur between visit 1 and visit 2. It will proceed as follows: 
• Record any AEs occurr ing since last visit and any that occur during this visit 
• Issues with titration schedule  
• Record any changes in concomitant medications  
Visit 2  (Week 2 ) 
Visit (Week 2 ) as follows:  
• Physical and neurological examination and height and weight 
• Vital signs (including systolic and diastolic blood pressure, radial pulse rate, and body 
temperature): performed after the subject has been in a sitting position for 3–5 minutes 
• Collect seizure diary and review entries  
• Record any AEs occurring since last visit and any that occur during this visit 
• Record any changes in concomitant medications  
• Complete the following assessments: 
o Caregiver  and Investigator  Global Impression of Change  
o QOLCE  
o PEDS -QOL  
• Blood draw for Complete blood count (CBC), comprehensive metabolic panel (CMP) Serum/Urine human chorionic gonadotropin (HCG), as applicable (sample taken only for female subjects of childbearing potential)  
• Urinalysis  
• Urine or serum THC  
• Dispense new seiz ure diary and review instructions for completion 
• Dispense study drug and review administration instructions 
• Instruct subject to return in 4 weeks for Visit 3  
 
Study number:  s18-01530   Page 20 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  Visit 3 (Week 6 ) 
The subject will return to the site for Visit 3.  Procedures at Visit 3 will pro ceed as follows:  
• Physical and neurological examination and height and weight 
• Vital signs (including systolic and diastolic blood pressure, radial pulse rate, and body 
temperature): performed after the subject has been in a sitting position for 3–5 minutes 
•  EKG and echocardiogram  
• Collect seizure diary and review entries  
• Record any AEs occurring since last visit and any that occur during this visit 
• Blood draw for Complete blood count (CBC), comprehensive metabolic panel (CMP) Serum/Urine human chorionic gonadotropin (HCG), as applicable (sample taken only for female subjects of childbearing potential)  , and antiepileptic medication levels  
• Urinalysis  
• Urine or serum THC  
• Complete the following assessments: 
o Caregiver  and Investigator  Global Impression of Change  
o QOLCE  
o PEDS -QOL  
• Record any changes in concomitant medications  
• Dispense new seizure diary and review instructions for completion 
• Review returned study drug and compliance 
• Dispense study drug and review administration instructions 
• Instruct subject to return in 4 weeks for Visit 4  
Safety call telephone  
The safety  call will occur between visit 3 and visit 4 . It will proceed as follows: 
• Record any AEs occurring since last visit and any that occur during this visit 
• Record any changes in concomitant medications  
Visit 4 (Week 10) 
The subject will return to the site for Visit 4.  Visit 4 will proceed as follows: 
• Physical and neurological examination and height and weight 
• Vital signs (including systolic and diastolic blood pressure, radial pulse rate, and body 
temperature): performed after the subject has been in a sitting position for 3–5 minutes 
• Collect seizure diary and review entries  
• Record any AEs occurring since last visit and any that occur during this visit 
• Record any changes in con comitant medications  
• Complete the following assessments: 
o Caregiver  and Investigator  Global Impression of Change  
o QOLCE  
o PEDS -QOL  
Study number:  s18-01530   Page 21 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  • Blood draw for Complete blood count (CBC), comprehensive metabolic panel (CMP) 
Serum/Urine human chorionic gonadotropin (HCG), as applicable (sample taken only for 
female subjects of childbearing potential), and antiepileptic medication levels  
• Urinalysis  
• Urine or serum THC  
• Dispense new seizure diary and review instructions for completion 
• Dispense study drug and review administration instructions 
• Instruct subject to return in 4 weeks for Visit 5  
Safety call telephone  
The safety call will occur between visit 4 and visit 5. It will proceed as follows: 
• Record any AEs occurring since last visit and any that occur during this visit 
• Record any changes in concomitant medications  
Visit 5 /End of study/ End of treatment/ Withdrawal visit (Week 14) 
Visit 5  will proceed as follows: 
• Physical and neurological examination and height and weight 
• Vital signs (including systolic and diastolic bloo d pressure, radial pulse rate, and body 
temperature): performed after the subject has been in a sitting position for 3–5 minutes 
• EKG and echocardiogram  
• Collect seizure diary and review entries  
• Record any AEs occurring since last visit and any that occur d uring this visit 
• Record any changes in concomitant medications  
• Complete the following assessments: 
o Caregiver  and Investigator  Global Impression of Change  
o QOLCE  
o PEDS -QOL  
• Blood draw for Complete blood count (CBC), comprehensive metabolic panel (CMP) 
Serum/Ur ine human chorionic gonadotropin (HCG), as applicable (sample taken only for 
female subjects of childbearing potential), and antiepileptic medication levels  
• Urinalysis  
• Urine or serum THC  
• For those subjects who have responded (response level ≥  40%) and wi ll like to continue in to 
the extension study: 
o Dispense new seizure diary and review instructions for completion 
o Dispense study drug and review administration instructions 
o Instruct subject to return in 12 weeks for Extension visit 1  
• For those subjects who have not responded and will not continue in to the extension study: 
o Taper schedule will be given  
o Subject have final post taper follow up in 4 weeks after the last dose  
Study number:  s18-01530   Page 22 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  7.5.2 Extension  
Extension visits 
If study medication provide benefit to the subject ( response level ≥  40%) , study medication will 
be provided until FDA approval or program discontinuation by Zogenix. The subject will return 
to the site every 12 weeks for extension visits. This includes: 
•  Physical and neurological examination and height and  weight  
• Vital signs (including systolic and diastolic blood pressure, radial pulse rate, and body 
temperature): performed after the subject has been in a sitting position for 3–5 minutes 
• EKG and echocardiogram  
• Collect seizure diary and review entries  
• Record any AEs occurri ng since last visit and any that occur during this visit 
• Record any changes in concomitant medications  
• Complete the following assessments: 
o Clinical Caregiver/Investigator Global Impression of Change 
o QOLCE  
o PEDS -QOL  
• Blood draw for Complete blood count (CBC), comprehensive metabolic panel (CMP) Serum/Urine human chorionic gonadotropin (HCG), as applicable (sample taken only for female subjects of childbearing potential), and antiepileptic medication levels  
• Urinalysis  
• Urine or serum THC  
• Disp ense new seizure diary and review instructions for completion 
• Dispense masked study drug and review administration instructions 
• Instruct subject to return in 12 weeks for next visit  
Safety call telephone 
The safety call will occur between extension visit.  It will proceed as follows: 
• Record any AEs occurring since last visit and any that occur during this visit 
• Record any changes in concomitant medications  
7.5.3 End of treatment 
End of treatment/ Withdrawal visit  End of treatment/withdrawal will proceed as follo ws: 
• Physical and neurological examination and height and weight 
• Vital signs (including systolic and diastolic blood pressure, radial pulse rate, and body 
temperature): performed after the subject has been in a sitting position for 3–5 minutes 
• EKG and echoc ardiogram  
• Collect seizure diary and review entries  
• Record any AEs occurring since last visit and any that occur during this visit 
Study number:  s18-01530   Page 23 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  • Record any changes in concomitant medications  
• Complete the following assessments: 
o Clinical  Caregiver/Investigator  Global Imp ression of Change 
o QOLCE  
o PEDS -QOL  
• Blood draw for Complete blood count (CBC), comprehensive metabolic panel (CMP) 
Serum/Urine human chorionic gonadotropin (HCG), as applicable (sample taken only for female subjects of childbearing potential), and antiepilept ic medication levels  
• Urinalysis  
• Urine or serum THC  
• Subject have final post taper follow up in 4 weeks after the last dose  
Post Taper Follow- up  
The Follow-up visit is to occur 4 weeks after the last dose of study drug,  It will proceed as follows: 
• Record any AEs occurring since last visit and any that occur during this visit 
• Record any changes in concomitant medications  
• Return any study medications  
 
7.5.4 Unscheduled Visit  
• Record any AEs occurring since last visit and any that occur during this visit 
• Record any changes in concomitant medications 
7.6 Concomitant Medications  
All concomitant prescription medications taken during study participation will be recorded on 
the case report forms (CRFs). For this protocol, a prescription medication is defined as a medi cation that can be prescribed only by a properly authorized/licensed clinician. Medications 
to be reported in the CRF are concomitant prescription medications, over- the-counter 
medications and non-prescription medications. Epidiolex is only acceptable CBD preparation that may be included. All other formulations are excluded.  
7.7 Prohibited Medications, Treatments, and Procedures 
Treatment with other investigational medications will not be permitted.  
7.8 Participant Access to Study Agent at Study Closure 
Zogenix wi ll continue to supply study medication to those subjects that received benefit from the 
study after participant are no longer enrolled in the study.  
8 Assessment of Safety  
8.1 Specification of Safety Parameters  
• Treatment- emergent adverse events will be continuously reported throughout the study 
Study number:  s18-01530   Page 24 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  • Each patient will undergo a Doppler echocardiographic (ECHO) and ECG examinations 
during the baseline period and again at weeks 6, 14, and every 3 months thereafter during 
the extension study and End of treatment/withdrawal visits.  
• All ECHOs readings will be sent to the site for evaluation and will be graded as to 
presence and severity of cardiac valve regurgitation  
8.1.1  Definition of Adverse Events (AE)  
An adverse event  (AE) is any symptom, sign, illness or experience that develops or 
worsens in severity during the course of the study.  Intercurrent illnesses or injuries should 
be regarded as adverse events.  Abnormal results of diagnostic procedures are considered to be adverse events if the abnormality:  
• results in study withdrawal 
• is associated with a serious adverse event  
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests  
• is considered by the investigator to be of clinical significance  
 
8.1.2  Definition of Serious Adverse Events (SAE)  
Serious Adverse Event  
Adverse events are classified as serious or non -serious.  A serious adverse event  is any AE 
that is:  
• fatal 
• life-threatening  
• requires or prolongs hospital stay 
• results  in persistent or significant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medical event 
 Important medical events are those that may not be immediately life threatening, but are clearly of major clinical significance. They may jeopardize the subject, and may require intervention to prevent one of the other serious outcomes noted above. For example, drug overdose or abuse, a seizure that did not result in in -patient hospitalization, or intensive treatment of bronchospasm in 
an emergency department would typically be considered serious.   All adverse events that do not meet any of the criteria fo r serious should be regarded as non-
serious adverse events .  
8.1.3 Definition of Unanticipated Problems (UP)  
Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets all of the following criteria:  
• Unexpected in  nature, severity, or frequency  (i.e. not described in study- related 
documents such as the IRB-approved protocol or consent form, the investigators brochure, etc) 
• Related or possibly related to participation in the research  (i.e. possibly related means 
there is a reasonable possibility that the incident experience, or outcome may have been 
Study number:  s18-01530   Page 25 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  caused by the procedures involved in the research) 
• Suggests that the research places subjects or others at greater risk of harm  (including 
physical, psychological, economic, or social harm).  
 
8.2
 Classification of an Adverse Event  
8.2.1 Severity of Event  
The following grading system  will be used to describe severity. 
• Grade 1: Mild  – Events require minimal or no treatment and do not interfere with the 
participant’s daily activities.  
• Grade 2: Moderate – Events result in a low level of inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference with functioning. 
• Grade 3: Severe – Events interrupt a participant’s usual daily activity and may requi re 
systemic drug therapy or other treatment. Severe events are usually potentially life -
threatening or incapacitating.  
8.2.2 Relationship to Study Agent  
The clinician’s assessment of an AE's relationship to study agent (drug, biologic, 
device) is part of the documentation process, but it is not a factor in determining what is or is not reported in the study. If there is any doubt as to whether a clinical observation is an AE, the event should be reported. All AEs must have their relationship to study agent assessed. In a clinical trial, the study product must always be suspect. To help assess, the 
following guidelines are used:  
 
• Related – The AE is known to occur with the study agent, there is a reasonable possibility that the study agent caused the AE, or ther e is a temporal relationship between the study 
agent and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study agent and the AE. 
• Not Related  – There is not a reasonable possibility that the administra tion of the study 
agent caused the event, there is no temporal relationship between the study agent and event onset, or an alternate etiology has been established.  
For all collected AEs, the clinician who examines and evaluates the participant will 
determ ine the AE’s causality based on temporal relationship and his/her clinical judgment. 
The degree of certainty about causality will be gr aded using the categories below: 
 
• Definitely Related  – There is clear evidence to suggest a causal relationship, and other 
possible contributing factors can be ruled out. The clinical event, including an abnormal laboratory test result, occurs in a plausible time relationship to drug administration and cannot be explained by concurrent disease or other drugs or chemicals. The response to withdrawal of the drug (dechallenge) should be clinically plausible. The event must be pharmacologically or phenomenologically definitive, with use of a satisfactory rechallenge procedure if necessary.  
• Probably Related  – There is evidence to suggest a causal relationship, and the influence 
of other factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs within a reasonable time after administration of the drug, is unlikely to be 
Study number:  s18-01530   Page 26 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  attributed to concurrent disease or other drugs or chemicals, and follows a clinically 
reasonable response on withdrawal (dechallenge). Rechallenge information is not required to fulfill this definition.  
• Possibly Related  – There is some evidence to suggest a causal relationship (e.g., the event 
occurred within a reasonable time after administration of the trial medication). However, other factors may have contributed to the event (e.g., the participant’s clinical condition, other concomitant events). Although an AE may rate only as “possibly related” soon after discovery, it can be flagged as requiring more information and later be upgraded to “probably related” or “definitely related,” as appropriate.  
• Unlikely to be related  – A clinical event, including an abnormal laboratory test result, 
whose temporal relationship to drug administration makes a causal relationship improbable (e.g., the event did not occur within a reasonable time after administration of the trial medication) and in which other drugs or chemicals or underlying disease provides plausible explanations (e.g., the participant’s clinical condition, other concomitant treatments).  
• Not Related  – The AE is completely independent of study drug administration, and/or 
evidence exists that the event is definitely related to another etiology. There must be an alternative, definitive etiology documented by the clinician.  
8.2.3 Expectedness  
Principal Investigator will be responsible for determining whether an AE is expected or unexpected. An AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described for the study agent.  
8.3 Time Period and Frequency for Event Assessment and Follow- Up 
The occurrence of an AE or SAE may come to the attention of study personnel during 
study visits and interviews of a study participant presenting for medical care, or upon review by a study monitor. All AEs including local and systemic reactions not meeting the criter ia for 
SAEs will be captured on the appropriate CRF. Information to be collected includes event description, time of onset, clinician’s assessment of severity, relationship to study product (assessed only by those with the training and authority to make a diagnosis), and time of resolution/stabilization of the event. All AEs occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution. 
Any medical condition that is present at the time that the participant is screened will be 
considered as baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in the data collection sy stem throughout the study. 
Changes in the severity of an AE will be documented to allow an assessment of the 
duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each episode. 
The PI will record all reportable events with start dates occurring any time after informed 
consent is obtained until 7 (for non- serious AEs) or 30 days (for SAEs) after the last day of study 
participation. At each study visit, the investigator will inquir e about the occurrence of AE/SAEs 
since the last visit. Events will be followed for outcome information until resolution or stabilization.  
All unresolved adverse events should be followed by the investigator until the events are 
Study number:  s18-01530   Page 27 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  resolved, the subject is l ost to follow -up, or the adverse event is otherwise explained.  At the last 
scheduled visit, the investigator should instruct each subject to report any subsequent event(s) 
that the subject, or the subject’s personal physician, believes might reasonably be related to participation in this study.  The investigator should notify the study sponsor of any death or adverse event occurring at any time after a subject has discontinued or terminated study participation that may reasonably be related to this study.  The sponsor should also be notified if the investigator should become aware of the development of cancer or of a congenital anomaly in a subsequently conceived offspring of a subject that has participated in this study.  
8.4 Reporting Procedures – Notifying the IRB  
Federal regulations require timely reporting by investigators to their local IRB of 
unanticipated problems posing risks to subjects or others. The following describes the NYULMC IRB reporting requirements, though Investigators at participating sites are responsible for meeting the specific requirements of their IRB of record.  
 
Report Promptly, but no later than 5 working days: 
Researchers are required to submit reports of the following problems promptly but no 
later than 5 working days from the time  the investigator becomes aware of the event:  
• Unanticipated problems including adverse events that are unexpected and related  
– Unexpected:  An event is “unexpected” when its specificity and severity are not 
accurately  reflected in the protocol- related do cuments, such as the IRB-approved 
research protocol, any applicable investigator brochure, and the current IRB-approved informed consent document and other relevant sources of information, such as product labeling and package inserts. – Related to the research procedures : An event is related to the research 
procedures if in the opinion of the principal investigator or sponsor, the event was more likely than not to be caused by the research procedures.  
– Harmful:  either caused harm to subjects or others, or placed them at increased 
risk 
 
 Other Reportable events:  
The following events also require prompt reporting to the IRB, though no later than 5 working days: 
• Complaint of a research subject when the complaint indicates unexpected risks or the complaint cannot be resolved by the research team.  
• Protocol deviations or violations (includes intentional and accidental/unintentional deviations from the IRB approved protocol) for any of the following situations: – one or more participants were placed at increased risk of harm – the event has the potential to occur again – the deviation was necessary to protect a subject from immediate harm • Breach of confidentiality •  Incarceration of a participant when the research was not previously approved under Subpart C and the investigator believes it is in the best interest of the subject to remain on the study. •  New Information indicating a change to the risks or potential benefits of the research, in  terms of severity or frequency. (e.g. analysis indicates lower -than-
Study number:  s18-01530   Page 28 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  expected response rate or a more severe or frequent side effect; Other research 
finds arm of study has no therapeutic value; FDA labeling change or withdrawal from market). 
 
Reporting Process  
The reportable events noted above will be reported to the IRB using the form: “Reportable Event Form ” or as a written report of the event (including a description of 
the event with information regarding its fulfillment of the above criteria, follow -
up/resolution and need for revision to consent form and/or other study documentation). 
8.4.1 Adverse Event Reporting and Serious Adverse Event Reporting  
Adverse events and serious adverse events will be reported to the IRB on a spreadsheet including timeframe, severity, relatedness and action during annual reporting. 
 
8.4.2 Unanticipa ted Problem Reporting  
 Incidents or events that meet the OHRP criteria for UPs require the creation and completion of an UP report form. It is the site investigator’s responsibility to report UPs to their IRB and to the study sponsor. The UP report will include the following information:  
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project number; 
• A detailed description of the event, incident, experience, or outcome; 
• An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP. 
 To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
 
• UPs that are SAEs will be rep orted to the IRB and to the study sponsor within 7 
days of the investigator becoming aware of the event.  
• Any other UP will be rep orted to the IRB and to the study sponsor within 7 days 
of the investigator becoming aware of the problem. 
• All UPs should be reported to appropriate institutional officials (as required by an institution’s written reporting procedures), the supporting agency head (or designee), and OHRP within7 days of the IR’s re ceipt of the report of the problem 
from the investigator. 
 
8.4.3  Reporting of Pregnancy  
The investigator should also be notified of pregnancy occurring during the study but confirmed after completion of the study. In the event that a subject/subject’s partner is subsequently found to be pregnant after the volunteer is included in the study, then consent will be sought from the partner and, if granted, any pregnancy will be followed 
Study number:  s18-01530   Page 29 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  and the status of mother and/or child will be reported to the sponsor after delivery.  
 Any subject reporting a pregnancy during the study will be withdrawn from the study and should complete the taper schedule. 
8.5 Reporting Procedures – Notifying the Study Sponsor  
The study clinician will complete a SAE Form within the following timelines:  
• All deaths and immediately life -threatening events, whether related or unrelated, 
will be recorded on the SAE Form and submitted to the DCC/study sponsor within 24 hours of site awareness. See Section 1, Key Roles for contact information. 
• Other SAEs regardless of relationship will be submitted to the DCC/study sponsor within 72 hours of site awareness.  
 
All SAEs will be followed until satisfactory resolution or until the site investigator deems 
the event to be chronic or the adherence to be stable. Other supporting documentation of the event may be requested by the DCC/study sponsor and should be provided as soon as possible.  
As a follow-up to the initial report, within the following 48 hours of awareness of the event, 
the investigator shall provide further information, as applicable, on the unanticipated event or the unanticipated problem in the form of a written narrative.  This should include a copy of the completed Unanticipated Problem form, and any other diagnostic information that will assist the understanding of the event.  Significant new information on ongoing unanticipated adverse effects shall be provided promptly to the study sponsor. 
8.6 Reporting Procedures – Notifying the FDA  
The drug sponsor is required to report certain study events in an expedited fashion to the FDA.  These written notifications of adverse events are referred to as IND  safety reports. The following 
describes the IND safety reporting requirements by timeline for reporting and associated type of event:  
 
• Within 7 calendar days (via telephone or facsimile report)  
Any study event that is :  
– associated with the use of the study drug  
– unexpected,  
– fatal or life -threatening  
 
• Within 15 calendar days (via written report)  
Any study event that is :  
– associated with the use of the study drug,  
– unexpected, and 
– serious, but not fatal or life- threatening  
-or- 
– a previous advers e event that was not initially deemed reportable but is later 
found to fit the criteria for reporting (reporting within 15 calendar days from when event was deemed reportable). 
Any finding from tests in laboratory animals that:  
Study number:  s18-01530   Page 30 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  – suggest a significant risk for human subjects including reports of mutagenicity, 
teratogenicity, or carcinogenicity.  
 
Additional reporting requirements  
Sponsors are also required to identify in IND safety reports all previous reports concerning 
similar adverse events and to analyze the significance of the current event in light of the previous reports.  
 
Reporting Process  
Adverse events may be submitted on FDA Form 3500A or in a narrative format. If supplied as in 
a narrative format, the minimum information to be supplied is noted above at the beginning of section 8.3. The contact information for submitting IND safety reports is noted below:  [Include the FDA Division, contact person, telephone number and fax number here]  
8.7 Study Halting Rules  
If the investigator becomes aware of conditions such as adverse events that if additional similar events occurred may warrant halting or termination of the clinical study, the investigator will notify Zogenix within 24 hours.  They will convene an ad hoc meeting by teleconference or in writin g as soon as possible so that both parties can discuss and 
agree on the best path forward which may include: 
– Modification to the study protocol 
– Modification to safety monitoring 
– Steps to be taken if additional similar adverse events are observed  
 
8.8 Safety Oversight  
It is the responsibility of the Principal Investigator to oversee the safety of the study at 
his/her site.  This safety monitoring will include careful assessment and appropriate reporting of adverse events as noted above, as well as the construction and implementation of a site data and safety -monitoring plan. Medical monitoring will include an  assessment of the number and type 
of serious adverse events.  
9 Statistical Considerations  
9.1 Statistical and Analytical Plans (SAP)  
There will be no formal statistical methodology but rather descriptive statistics to 
quantify the primary and secondary outcome measures as well as the frequency and severity of adverse effects . All subjects participating in this study will have their data analyzed with 
descriptive s tatistics for both the  primary and secondary analyses. 
9.2 Sample Size  
No statistical methods were used to determine the sample size for this study. The 
principal investigator has requested for expanded access use, 21 CFR 312.315 in an intermediate size patien t population of 10. The total number of subjects expected to participate at NYU 
Comprehensive Epilepsy Center is 10. 
Study number:  s18-01530   Page 31 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  10 Source Documents and Access to Source Data/Documents  
Source data is all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source 
data are contained in source documents.  Examples of these original documents, and data records include: hospital records, clinical and office char ts, laboratory notes, memoranda, subjects’ 
diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject files, and 
records kept at the pharmacy, at the laboratories, and at medico -technical departments involved 
in the clinical trial. It is acceptable to use CRFs as source documents. If this is the c ase, it should 
be stated in this section what data will be collected on CRFs and what data will be collected from other sources. 
The study case report form (CRF) is the primary data collection instrument for the study.  
All data requested on the CRF must be recorded.  All missing data must be explained.  If a space on the CRF is left blank because the procedure was not done or the question was not asked, write 
“N/D”.  If the item is not applicable to the individual case, write “N/A”.  All entries should be 
printed legibly in black ink.  If any entry error has been made, to correct such an error, draw a single straight line through the incorrect entry and enter the correct data above it.  All such changes must be initialed and dated.  DO NOT ERASE OR WHITE OU T ERRORS.  For 
clarification of illegible or uncertain entries, print the clarification above the item, then initial and date it . 
Access to study records will be limited to IRB -approved members of the study team. The 
investigator will permit study -related monitoring, audits, and inspections by the IRB/EC, the 
sponsor, government regulatory bodies, and University compliance and quality assurance groups of all study related documents (e.g. source documents, regulatory documents, data collection instruments, study data etc.).  The investigator will ensure the capability for inspections of applicable study -related facilities (e.g. pharmacy, diagnostic laboratory, etc.).  
Participation as an investigator in this study implies acceptance of potential inspection by 
government regulatory authorities and applicable University compliance and quality assurance offices.  
11 Ethics/Protection of Human Subjects  
11.1 Ethical Standard 
The investigator will ensure that this study is conducted in full conformity with 
Regulations for the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 
CFR Part 50, 21 CFR Part 56, and/or the ICH E6. 
11.2 Institutional Review Board  
The protocol, informed consent/assen t forms, recruitment materials, and all participant 
materials will be su bmitted to the IRB for review and approval. Approval of both the protocol 
and the consent /assent  form must be obtained before any participant is enrolled. Any amendment 
to the protocol will require review and approval by the IRB before the changes are impl emented 
to the study. All changes to the consent form will be IRB approved; a determination will be made regarding whether previously consented participants need to be re-consented. 
Study number:  s18-01530   Page 32 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  11.3 Informed Consent Process 
11.3.1  Consent/Assent and Other Informational Documents Provided to Participants  
Consent forms describing in detail the study agent, study procedures, and risks are 
given to the participants.  Capacity assessment will be conducted by Dr. Orrin Devinsky. 
He is board certified Neurologist and Epileptologist and Di rector of both the NYU 
Comprehensive Epilepsy Center and St. Barnabas Institute for Neurology & 
Neurosurgery. He is experienced in dealing with various neurological diseases and multiple clinical trials.   
Capacity will be assessed through neurological examinations conducted by the 
physician as well as documented learning and/or development delays. Previous neurological records and neuropsychological assessments will be used to determine whether the subject has t  the capacity to assent. Consent forms descri bing in detail the 
study agent, study procedures, and risks will be given to the parent/guardian and written documentation of informed consent is required prior to starting intervention/administering study product. Dr. Orrin Devinsky will obtain consent and explain and/or answer any questions that should arise. This will be done in a private patient examination room at the NYU Comprehensive Epilepsy Center. The consent materials are submitted with this protocol. Study participant and written documentation of informed consent is required prior to starting intervention/administering study product.  
11.3.2  Consent Procedures and Documentation  
Informed consent is a process that is initiated prior to the individual’s agreeing to 
participate in the study and continues throughout the individual’s study participation. Extensive discussion of risks and possible benefits of participation will be provided to the participants and their families. Consent forms will be IRB -approved and the participant 
will be asked to read and re view the document. The investigator will explain the research 
study to the participant and answer any questions that may arise. All participants will receive a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants. Participants will have the opportunity to carefully review the written consent form and ask questions prior to signing. The participants should have the opportunity to discuss the study with their surrogates or think about it prior to agreeing to participate. The participant will sign the informed consent document prior to any procedures being done specifically for the study. The participants may withdraw consent at any time throughout the course of the trial. A copy of the signed informed consent document will be given to 
the participants for their records. The rights and welfare of the participants will be protected by emphasizing to them that the quality of their medical care will not b e 
adversely affected if they decline to participate in this study.  For individuals under 18 
years of age, assent will be obtained using an IRB approved age-appropriate assent form. If a subject turns 18 during study participation, he or she will be re-consented as an adult. For subjects 18 or older, consent will be obtained with the IRB approved consent form.  
A copy of the signed informed consent document will be stored in the subject’s 
research record. The consent process, including the name of the indivi dual obtaining 
consent, will be thoroughly documented in the subject’s research record. Any alteration to the standard consent process (e.g. use of a translator, consent from a legally authorized representative, consent document presented orally, etc.) and the justification for such 
Study number:  s18-01530   Page 33 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  alteration will likewise be documented.  
11.4 Participant and Data Confidentiality  
Information about study subjects will be kept confidential and managed according to the 
requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  
Those regulations require a signed subject authorization informing the subject of the following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability to use all information collected prior to the revocation of subject 
authorization.  For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study period. 
Participant confidentiality is strictly held in trust by the participating investigators, their 
staff, and the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples and genetic tests in addition to the clinical information relating to 
participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the stud y or the data will 
be released to any unauthorized third party without prior written approval of the sponsor. 
The study monitor, other authorized representatives of the sponsor, representatives of the 
IRB or pharmaceutical company supplying study product may inspect all documents and records required to be maintained by the investigator, including but not limited to, medical records (office, clinic, or hospital) and pharmacy records for the participants in this study. The clinical study site will permit acc ess to such records.  
The study participant’s contact information will be securely stored at each clinical site for 
internal use during the study. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by local IRB and Institutional regulations.  
Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be transmitted to and stored at NYU Langone Medical Center. This will not include the participan t’s contact or identifying information. Rather, individual participants and 
their research data will be identified by a unique study identification number. The study data entry and study management systems used by clinical sites and by NYU Langone Medical Center research staff will be secured and password protected. At the end of the study, all study databases will be de- identified and archived at the NYU Langone Medical Center.  
12 Data Handling and Record Keeping  
12.1 Data Collection and Management Responsibilities 
Data collection is the responsibility of the clinical trial staff at the site under the 
supervision of the site PI. The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.  
All source docum ents should be completed in a neat, legible manner to ensure accurate 
interpretation of data. Black ink is required to ensure clarity of reproduced copies. When making changes or corrections, cross out the original entry with a single line, and initial and date the 
Study number:  s18-01530   Page 34 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  change. We will not: ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON 
THE ORIGINAL.  
Copies of the electronic CRF (eCRF ), if used, will be provided for use as source 
documents and maintained for recording data for each participant enrolled in the study. Data reported in the eCRF derived from source documents should be consistent with the source documents or the discrepancies should be explained and captured in a progress note and maintained in the participant’s official electronic study record.  
Clinical data (including AEs, concomitant medications, and expected adverse reactions 
data) and clinical laboratory data will be entered into  study site database. Clinical data will be 
entered directly from the source documents. 
12.2 Study Records Retention  
Study documents will be retained for the longer of 3 years after close- out, 5 years after 
final reporting/publication, or 2 years after the last approval of a marketing application is approved for the drug for the indication for which it is being investigated or 2 years after the investigation is discontinued and FDA is notified if no application is to be filed or if the application has not been approved for such indication. No records will be destroyed without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no longer need to be retained. 
12.3  Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or Manual 
of Procedures (MOP) re quirements. The noncompliance may be either on the part of the 
participant, the investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by the site and implemented promptly. 
These practices are consistent wi th ICH E6: 
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3 
• 5.1 Quality Assurance and Quality Control, section 5.1.1 
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2. 
It is the responsibility of the site PI/study staff to use continuous vigilance to  identify and 
report deviations. Protocol deviations must be reported to the local IRB at the annual continuation.  
13 Study Finances  
13.1 Funding Source  
Zogenix will provide study medication and funding to support this study. 
13.2 Costs to the Participant  
Zogenix will prov ide the study medicine free of charge to participating research subjects for 
the duration of this study.  
The subjects will be receiving medical care as a part of  this research study. Subjects or their 
insurance company will not be charged or held responsible or the costs of that care. All costs 
related to procedures and assessments associated with participating in this study will be  free of 
charge.  
Procedures that are part of routine care or to assess the subject’s health but are not mandatory 
for the study will not be covered. The subject’s individual insurance or government health 
Study number:  s18-01530   Page 35 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Interventional Template Version: 28 APR 2017  insurance program may not cover certain services, items, or procedures. This may be discussed 
with the  subject’s insurance carrier in advance. The subject/paren t/legal guardian will be 
responsible for any co -payments and/or deductibles for services rendered. 
The subject and/or the subject’s health insurance may be billed for the costs of medical care 
during this study if these expenses would have happened even if the subject was not in the study, or if the subject’s insurance agrees in advance to pay. If the subject has health insurance, the cost 
of these services will be billed to the subject’s insurance company. If the subject’s insurance does not cover these co sts or the subject does not have insurance, these costs will be 
the subject’s responsibility.  
14 Conflict of Interest Policy  
The independence of this study from any actual or perceived influence, such as by the 
pharmaceutical industry, is critical. Therefore, any actual conflict of interest of persons who have a role in the design, conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore, persons who have a perceived conflict of interest will be required to have such conflicts managed in a way that is appropriate to their participation in the trial. All 
study group members will disclose all conflicts of interest and will establish a mechanism for the 
management of all reported dualities of interest.   
Any investigator who has a conflict of interest with this study (patent ownership, royalties, 
or financial gain greater than the minimum allowable by their institution, etc.) must have the conflict reviewed by the NYU Langone Conflict of Interest Management Unit (CIMU) with a Committee -sanctioned conflict management plan that has been reviewed and approved by the 
study sponsor prior to par ticipation in this study. All NYULMC investigators will follow the 
applicable conflict of interest policies.  
15  References  
1. Devinsky, O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson G. 
Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. 
Lancet Neurol . 2016 Sep;15(10):1075-88. 
 2. Guerrini R, Parrini E. Epilepsy in Rett syndrome, and CDKL5 -
  and FOXG1 -gene-related 
encephalopathies.  Epilepsia . 2012 De c ;53(12):2067-78. 
 3. Lagae  ,Lieven; Sullivan, Joseph E.; Cross ,J. Helen; Devinsky ,Orri ,; Guerrini,Renzo, 
Meyer ,Anna; Knupp,Kelly G.; Laux , Linda C.,; Miller, Ian; Nikanorova, Marina; 
Polster ,Tilman; Talwar , Dinesh; Farfel ,Gail M.; Galer ,Bradley S .; Gammaitoni,Arnold; 
Morrison ,Glenn; Mistry, Arun; and Ceulemans, Berten. ZX008 (Fenfluramine) in Dravet 
Syndrome: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Abstract. Abst. 2.434), 2017. 
4. ZX008. Fenfluramine Hydrochloride. Investigator’s Brochure, Edition 5. Z ogenix  
International L imited: A W holly O wned  Subsidiary of Zogenix , Inc. 28 Apr 2017. 
  
Study number:   Page 36 
Version: 09 Sep 2020  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 05 JAN 2017  
  
16. APPENDIX 
APPENDIX 1 – LIST OF PROHIBITED  CONCOMITANT  
MEDICATIONS  
 
Generic  Name  Generic  Name  
alfentanil  naratriptan  
almotriptan  nefazodone  
alprenolol  nortriptyline  
amitriptyline  ondansetron  
amphetamine  oxcarbazepine  
astemizole  oxycodone  
atomoxetine  paroxetine  
bufuralol  pergolide  
bupropion  perphenazine  
buspirone  phenacetin  
cafergot  phenobarbital  
Cannabidiol : that is not Epidiolex  phenytoin  
carbamazepine  promethazine  
cerivastatin  propafenone  
cabergoline  retigabine/ezogabine  
citalopram  risperidone  
clomipramine  ritonavir  
codeine  rizatriptan  
cyproheptadine  selegiline  
dasatinib  sertraline  
desipramine  sumatriptansertraline  
dextromethorphan  telaprevir  
duloxetine  THC and  derivatives  
eletriptan  tramadol  
encainide  trazodone  
ergotamine  tartrate  vortioxetine  
eslicarbazepine  zolmitriptan  
felbamate  zuclopenthixol  
fentanyl   
fluoxetine   
fluvoxamine   
frovatriptan   
imipramine   
interferon   
levacetylmethadol  (LAAM)   
Study number:  s18-01530   Page 37 
Version: 11 Jan 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 28 APR 2017  linezolid   
meperidine   
methadone   
metoclopramide   
mexiletine   
 